Our Mission

We will leverage our proprietary product candidate, pelareorep (pela), an investigational first-in-class double-stranded RNA immunotherapeutic agent, to establish a platform immunotherapy for the treatment of gastrointestinal (GI) tumors. We believe GI tumors are the largest unmet medical need in oncology and seek to provide patients across multiple GI tumors with a tolerable immunotherapy that increases the chances they will live longer lives.

Leadership

Jared Kelly
Jared Kelly
Chief Executive Officer & Director
Kirk Look, CA, MSJ
Kirk Look, CA, MSJ
Chief Financial Officer
Thomas C. Heineman
Thomas C. Heineman, MD, PhD
Chief Medical Officer
Allison Hagerman, PEng, PMP, MBT
Allison Hagerman, PEng, PMP, MBT
Chief Technology Officer
Andrew Aromando
Andrew Aromando
Chief Business Officer
John McAdory
John McAdory
Executive Vice President, Strategy and Operations
circles background

Board of Directors

circles background

Gastrointestinal Tumor Scientific Advisory Board

Dirk Arnold, M.D., Ph.D., FESMO
Principal Investigator of the GOBLET study, Professor of Medicine, and Director of Asklepios Tumorzentrum Hamburg, Germany
Sanjay Goel, M.D., M.S., FASCO
Professor of Medicine and Director of the Phase I Program at Rutgers Cancer Institute of New Jersey
Deva Mahalingam, M.D., Ph.D.
Professor of Medicine, GI oncologist and Director of the Developmental Therapeutics Program, Lurie Cancer Center at Northwestern University
Van Morris, M.D.
Associate Professor in the Department of Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer Center in Houston, TX, and Section Chief for Colorectal Cancer
Eileen O’Reilly, M.D.
Winthrop Rockefeller Endowed Chair of Medical Oncology at Memorial Sloan Kettering Cancer Center in New York
Neil Segal, M.D., Ph.D.
Research Director of the Division of Gastrointestinal Oncology at Memorial Sloan Kettering Cancer Center in New York

Additional Scientific Advisors

Martine Piccart, MD, PhD
Honorary Professor of Oncology at the Université Libre de Bruxelles, Belgium, Scientific Director at the Institut Jules Bordet, Co-Founder and Chair of the Breast International Group (BIG).
Richard Vile, PhD
Professor of Immunology at the Mayo Clinic, Co-Director of the Gene and Virus Therapy program, and Director of Mayo’s Immuno-oncology program

Contact Us

For questions regarding our science, partnership opportunities, or other inquiries, we encourage you to reach out.

Get in touch